Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 8/20 | 0.40 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.39 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.39 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.39 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.39 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.39 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.39 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16057335 | 0.86 | PSEN1 (0.42) | BRD4ATAD2PSEN1PSEN2APH1B | |
| SCHEMBL15431081 | 0.81 | FAAH (0.43) | BRD4ATAD2FAAHMMP3MMP8 | |
| SCHEMBL346833 | 0.81 | OPRK1 (0.57) | OPRK1FAAH | |
| SCHEMBL16252317 | 0.81 | OPRK1 (0.57) | OPRK1FAAH | |
| Hydrochloric Acid SCHEMBL7432243 | 0.80 | FAAH (0.42) | BRD4ATAD2FAAHMMP3MMP8 | |
| SCHEMBL17443352 | 0.80 | HTR1D (0.46) | FAAHPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL29559031 | 0.80 | ALDH1A1 (0.56) | FAAH | |
| SCHEMBL2232699 | 0.80 | ALDH1A1 (0.56) | FAAH | |
| SCHEMBL21063897 | 0.80 | FAAH (0.40) | FAAHCYP1A2FFAR1 | |
| SCHEMBL9215130 | 0.80 | CYP1A2 (0.41) | FAAHCYP1A2FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9556311-B2 | Polyimide precursor composition, article prepared by using same, and display device including the article | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2017-01-31 | — | — | US | disclosed |
| US-9556311-B2 | Polyimide precursor composition, article prepared by using same, and display device including the article | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2017-01-31 | — | — | US | disclosed |
| US-20140024786-A1 | POLYIMIDE PRECURSOR COMPOSITION, ARTICLE PREPARED BY USING SAME, AND DISPLAY DEVICE INCLUDING THE ARTICLE | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2014-01-23 | — | — | US | disclosed |
| US-20140024786-A1 | POLYIMIDE PRECURSOR COMPOSITION, ARTICLE PREPARED BY USING SAME, AND DISPLAY DEVICE INCLUDING THE ARTICLE | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2014-01-23 | — | — | US | disclosed |
| EP-0971878-B1 | AMINE COMPOUNDS, THEIR PRODUCTION AND USE AS AMYLOID-BETA PRODUCTION INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2008-03-26 | — | — | EP | disclosed |
| US-7256204-B2 | Amine compounds, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-14 | — | — | US | disclosed |
| US-20040077867-A1 | Amine compounds, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-22 | — | — | US | disclosed |
| US-6613805-B2 | For therapy and prophylaxis of neurodegenerative diseases such as Alzheimer's disease, Down's syndrome, Parkinson's disease, Creutzfeldt-Jacob disease, amyotrophic sclerosis on lateral fasciculus, multiple sclerosis, and neurological disorders | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-09-02 | — | — | US | disclosed |
| US-20020032189-A1 | For therapy and prophylaxis of neurodegenerative diseases such as Alzheimer's disease, Down's syndrome, Parkinson's disease, Creutzfeldt-Jacob disease, amyotrophic sclerosis on lateral fasciculus, multiple sclerosis, and neurological disorders | THE UNIVERSITY OF TOKYO (JP) | 2002-03-14 | — | — | US | disclosed |
| US-6310107-B1 | (+)-6-(4-BIPHENYLYL)METHOXY-2-(2-(N,N-DIMETHYLAMINO)ETHYL)TETR ALIN, OR A SALT IS USEFUL FOR INHIBITING PRODUCTION AND/OR SECRETION OF AMYLOID-BETA PROTEIN | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032189-A1 | For therapy and prophylaxis of neurodegenerative diseases such as Alzheimer's disease, Down's syndrome, Parkinson's disease, Creutzfeldt-Jacob disease, amyotrophic sclerosis on lateral fasciculus, multiple sclerosis, and neurological disorders | PARK7, PSEN1, PRNP | BRD4 1526/4885ATAD2 1151/4885GRIN2B 236/4885 |
| US-20040077867-A1 | Amine compounds, their production and use | QSOX1, APP, NPR1 | BRD4 690/4885ATAD2 1072/4885GRIN2B 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.